drugset
drugset / Trial / NCT01524406

Safety Study of HPP593 in Subjects During and After Limb Immobilization

NCT01524406 ↗

Phase 1 Terminated 24 enrolled High Point Pharmaceuticals, LLC.
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a safety and tolerability study investigating the effect of HPP593 in healthy volunteers during and after limb immobilization.

Timeline

Start
2012-01
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavodelpar Small molecule — Oral

Indications

muscular atrophy